Introduction
============

Introduction of combined hexavalent vaccines for immunization of infants and toddlers has led to high vaccine coverage and a significant reduction in incidence of pediatric infectious diseases worldwide, including diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by *Haemophilus influenzae* type b (Hib).[@b1-ppa-9-1517] The delivery of vaccination programs is usually undertaken through primary care or through well-baby clinics. In Germany, vaccines are given by both physicians and nurses, but in some countries vaccines are given solely by nurses. Physicians and nurses are responsible for administering high volumes of vaccinations, so any innovative research that can provide insight into the views of these health care providers (HCPs) regarding vaccinations may help to support a more efficient process.

Vaccine preparation may require reconstitution, whereby the Hib component for an established hexavalent vaccine (Infanrix hexa: GlaxoSmithKline Biologicals, Middlesex, UK) has to be mixed with five other components prior to administration. In 2013, a new, fully liquid hexavalent vaccine (Hexyon: Sanofi Pasteur MSD, Lyon, France) was licensed in Europe. Several studies report that fully liquid vaccines can increase time efficiency.[@b2-ppa-9-1517]--[@b5-ppa-9-1517]

Other factors such as mishandlings and the number of steps involved with vaccine preparation may also be important to HCPs. Fully liquid vaccines may reduce vaccination wastage rates, but may have bulkier packaging which is difficult to store.[@b2-ppa-9-1517] Fully liquid vaccines have fewer preparation steps than non-fully-liquid based vaccines. The choice of fully liquid or non-fully-liquid vaccines may also simply be determined by the way clinics are organized and structured. The choice between different vaccines is dependent on a range of factors, such as time taken per vaccination, mishandlings, and possibly packaging. The importance of each of these factors in driving decisions is not clear. One method to understand the value of tangible and slightly less tangible features of a vaccine or vaccination program is through the use of stated preference methods such as discrete choice experiment (DCE). DCE methods can be used to understand the strength of preference or value that HCPs place on design features in vaccination devices. The validity and appropriateness of standardized methods for eliciting preferences for a vaccine or treatment in health care research are quite well understood.[@b6-ppa-9-1517],[@b7-ppa-9-1517] These methods provide information regarding the significance of different vaccine attributes for HCPs' decision making.

The present study was designed to reveal HCPs' preferences regarding injection devices for hexavalent vaccine programs in Germany. The survey explores the importance of different features (or attributes) of fully liquid and nonfully-liquid vaccines.

Methods
=======

Literature review
-----------------

A focused literature review was undertaken to identify the key attributes of interest to include in the DCE survey. The review examined research into vaccine delivery and vaccination devices. A search strategy was implemented across the EMBASE and MEDLINE databases to identify research on user preferences for vaccine devices.

Of the 99 titles which were identified from the search strategy, 10 were retrieved as abstracts and nine were directly relevant to the study objective.[@b2-ppa-9-1517]--[@b4-ppa-9-1517],[@b8-ppa-9-1517]--[@b13-ppa-9-1517] Only six studies provided any useful information. The literature review identified four broad themes. These themes related to time saving, vaccine safety (eg, needlesticks), vaccine accuracy in terms of dosage, and wastage. The literature review was limited however, and so, qualitative research with HCPs was undertaken to better understand the issues related to hexavalent vaccines.

HCP interviews
--------------

Telephone interviews were conducted with HCPs to further explore the findings from the literature review and to identify possible study attributes. A market research patient panel identified and recruited pediatricians (n=3) and nurses (n=2) based in Germany, who were currently responsible for preparing and/or administering at least 15 pediatric vaccinations per month. Interviews were conducted by an experienced German interviewer. The objective of the interviews was to identify the attributes of vaccination devices which may be important for HCPs. Participants were asked to describe each attribute and their experience while preparing and administering hexavalent vaccines for children.

The findings from the interviews are described here briefly. In terms of preparation time, participants explained that non-fully-liquid vaccines would take 1--2 minutes longer to prepare than fully liquid vaccines. When discussing the fully liquid vaccine devices, the participants considered that they had several possible advantages. These included being faster to prepare, more hygienic, and have lower chance of mishandlings and less risk of needlestick injuries. Fully liquid vaccines may also prevent any chance of dosing error by either failure to properly reconstitute the vaccine or by accidentally leaving some of the vaccine in the vial.

The physicians agreed that mishandlings were a very serious issue and that they had protocols in place to prevent this happening. When asked to describe their ideal device, all physicians agreed that it would be a ready-to-use (prefilled) device with a sharp needle or the option to change the needle and an easy-to-use plunger device.

Survey development
------------------

The findings from the qualitative interviews and the literature review were used to develop a preliminary list of attributes that was discussed and went through two rounds of review. Each attribute was described in terms of three distinct levels considered to reflect a relevant and realistic range for that attribute by the study team ([Table 1](#t1-ppa-9-1517){ref-type="table"}).

The final five attributes and their levels were combined into hypothetical choices (called choice sets) which included each attribute with a distinct level. The combination of attributes and levels was based on an orthogonal fractional factorial design which was folded over to produce the alternative choice sets. The survey included a participant information sheet/informed consent form, an introductory screen, sociodemographic form, questions regarding HCP's current vaccination experience, and the DCE survey.

It was translated into German and sent to four German HCPs (two pediatricians and two nurses) who were asked to complete the survey (as a pilot phase) before a cognitive debriefing telephone interview. These four participants were asked to comment on the clarity of the instructions, appropriateness of choices/questions, the face validity of the choices, overall length of the survey, and language used. From these interviews, seven linguistic changes were recommended, for example, to replace the word "Kleinkinder" (infants) with "Säüglinge und Kleinkinder" (toddlers and infants) to cover the relevant age group. These changes were implemented and translations checked before finalizing the survey. The final survey included a logical consistency check whereby one choice question was reversed and repeated.

Study sample
------------

HCPs, either pediatricians or nurses -- working in Germany -- who administer (or prepare) a minimum of 15 hexavalent vaccinations per month to children and who were not in paid employment with the pharmaceutical industry were recruited for the survey. Participants were recruited across medical practices in Germany using a convenience sampling method by a specialist recruitment company (May--June 2014).

Data collection
---------------

Participants were invited to participate through email, and if they chose to follow the link, they were then directed to the informed consent form. Once signed, participants entered the screening section of the survey, and if they were eligible, they began the survey. Upon completion of the survey, participants were reimbursed a small recommended fee.

Statistical analysis
--------------------

Sociodemographic and current vaccine usage data were analyzed as means, standard deviations, and frequencies or percentages. Data from the DCE survey were analyzed using a conditional logit model. This explored the impact of each attribute (independent variable) on the participants' choices (dependent variable). Analyses were separated by profession (physician and nurse). The conditional logit model evaluated choice responses after conditioning them on the attributes of the other vaccine alternatives available within the choice set. Hence, if, for example, "Hexavalent injection device A" was preferred in the choice set number 1, this preference was conditional on the attributes of "Hexavalent injection device B." The coefficients obtained from the logit model provided an estimate of the (log) odds ratios (ORs) of preference for attributes. In addition, interactions were explored to see whether there were any profession-specific differences in the preferences of HCPs. All analyses were conducted in SAS v.9.2 (SAS Institute Inc., Cary, NC, USA). Subgroup analyses explored how preferences varied by professions (physicians vs nurses), current role (administer only vs prepare and administer/prepare only), and HCP vaccine preference (non-fully-liquid vaccine vs fully liquid vaccine).

Results
=======

Participant characteristics
---------------------------

A total of 300 participants (n=150 physicians, n=150 nurses) completed the online survey ([Table 2](#t2-ppa-9-1517){ref-type="table"}). All participants completed the consistency check in the choice section correctly and were thus included in the analyses.

[Table 2](#t2-ppa-9-1517){ref-type="table"} presents the demographic data and clinical practice profile of all participants. The majority of physicians were male (69%) with a median age range from 51 to 54 years. The majority of nurses were female (63%) with a median age range of 35--40 years. Among the physicians, 69% only administered the vaccine, whereas the nurses prepared and sometimes administered the vaccines. All participants (nurses and physicians) were asked to consider the hexavalent vaccine they used most frequently and to describe this vaccine in terms of the attributes used in the DCE. For example, they identified if the vaccine was in a prefilled syringe (PFS) or not, what they perceived the risk of dosing errors to be, and how long preparation took. This question identified that the majority of the physicians currently use a vaccine which requires reconstitution (67%), whereas more nurses reported using a PFS (77%). Over half of the participants (59%) felt that the number of years that a hexavalent injection device had been available was not important and that it did not play a role in their choice of device. Participants reported that it took about 1 minute to prepare their current hexavalent vaccine. There were a variety of responses regarding mishandlings and dosage errors.

Participant preference findings
-------------------------------

### Physicians

All attributes were significant predictors of choice, which means that all attributes were an important influence on physicians' choices ([Table 3](#t3-ppa-9-1517){ref-type="table"}). The attribute "probability of dosage errors" was the most important attribute as indicated by the high ORs. Physicians were almost four times more likely to prefer a vaccine that had an associated dosage error rate of 1:1,000 compared with one that had an error rate of 1:100 (OR =3.62, 95% CI =3.10--4.22). "Preparation time" was also an important attribute, with participants 2.5 times as likely to prefer a vaccine that took 30 seconds to prepare compared to the one that took 2 minutes (OR =2.45, 95% CI =2.089--2.870). Participants preferred vaccines that would have been available on the market for more than 3 years (OR =2.26, 95% CI =1.94--2.63). Physicians also preferred a fully liquid vaccine more than a non-fully-liquid vaccine (OR =1.45, 95% CI =1.312, 1.602).

### Nurses

The data from nurses were similar to those from the physicians. The nurses also placed high value on "probability of dosage errors" and preferred a vaccine with the least probability of errors (OR =3.95, 95% CI =3.40--4.60). "Preparation time" and "probability of mishandlings" were also important attributes of choice whereby participants preferred vaccines that took least time to prepare (OR =2.24, 95% CI =1.93--2.61) and included least likelihood for mishandlings (OR =1.95, 95% CI =1.69--2.26). Nurses preferred vaccines which they had some experience of using (as opposed to a vaccine and device that had not been on the market previously), but this preference was not as strong as for the physicians. Nurses placed significantly higher value on a fully liquid vaccine than the physicians (OR =1.76, 95% CI =1.59--1.94), confirmed in independent analyses (*P*\<0.001).

Further interaction analyses explored whether there were significant differences in strength of preference by profession. Compared to nurses, the physicians placed significantly more value on "years of experience of using hexavalent vaccine"; and on injection devices which took less time to prepare (*P*\<0.01).

Analyses were conducted to compare the preferences of HCPs who prepared vaccines (including preparing and administering) compared to those who only administered the vaccine. Participants who prepared the vaccine had a significantly greater preference for a fully liquid vaccine (*P*\<0.01). Those HCPs who only administered the vaccine placed significantly higher value on avoiding "dosage errors" (*P*\<0.01).

Finally, interaction analyses were also conducted to determine whether preferences varied by the vaccine that the HCPs were using currently, fully liquid or nonfully-liquid vaccine. Participants who were currently using fully liquid vaccine placed significantly higher value on a fully liquid vaccine than participants who were using non-fully-liquid vaccine (*P*\<0.02). Participants who were using fully liquid vaccine placed less value on the years of experience they had with the vaccine (*P*\<0.01). The non-fully-liquid vaccine group had a significantly stronger preference for injection devices with shorter preparation time (*P*\<0.01) and on avoiding dosage errors than the fully liquid vaccine group (*P*\<0.01).

Discussion
==========

This study reports a survey of HCPs regarding the importance of different features of vaccination devices for hexavalent pediatric vaccines. The study used a DCE survey which is a well-recognized stated preference method. Vaccination programs are perhaps unique within medicine in terms of the number of patients that a HCP will treat. Some of the HCPs in this study reported that they administered as many as 250 doses of vaccine a month. Because of this high number of patients, there is potential for innovations in the design of devices to improve the efficiency of the service. This survey attempted to explore this aspect with HCPs. The survey specifically avoided aspects related to the safety or immunogenicity of vaccines because the immunogenicity and safety of the two hexavalent vaccines are considered to be similar.[@b14-ppa-9-1517] Instead the survey focused on issues such as the need for reconstitution, years of experience in using a vaccine, preparation time, and handling or dosage errors.

The study captured the views of physicians and nurses separately. At the outset of the study, we understood that in Germany generally vaccines were given to children by both physicians and nurses. However, the present data suggest that practice is much more variable. Over half of our nurse sample indicated that they prepare and administer the vaccine. Interestingly, 30% of the physicians prepare their vaccine as well as administer it.

The in-depth interviews with physicians and nurses during the survey development phase provided different information to the main DCE survey. In the qualitative interviews, the physicians describe mishandlings such as needlestick injuries as a rarity, which could lead to disciplinary action. In contrast, the survey data suggested that mishandlings occurred more frequently. Almost 15% of nurses (and 10% of physicians) indicated that they thought that mishandlings occurred at least once in every 200 patients. Dosing errors such as a failure to administer the entire vaccine or a failure to properly reconstitute were also reported to occur. A Time and Motion study performed in Belgium[@b5-ppa-9-1517] comparing preparation time with a fully liquid hexavalent vaccine (Hexyon, Sanofi Pasteur MSD) and a non-fully-liquid hexavalent vaccine (Infanrix hexa, GlaxoSmithKline Biologicals) has shown that mishandlings occurred five times more with the hexavalent vaccine that needs reconstitution (47 mishandlings with the non-fully-liquid hexavalent vaccine and 10 with the fully liquid hexavalent vaccine out of 192 preparations).

The DCE choice data provide useful insights into how HCPs view each aspect of the vaccination device. Overall, the HCPs preferred fully liquid vaccines. The samples were approximately 50% more likely to choose a vaccine if it was fully liquid. However, the nurses revealed a larger preference for fully liquid vaccines compared to the physicians. The use of fully liquid vaccines perhaps has more impact on the workload of nurses -- particularly those who are focused on the preparation of vaccines only. This is consistent with previous studies which report that fully liquid vaccines that did not require reconstitution, saved time, and were more efficient. Kumar et al[@b2-ppa-9-1517] reviewed a survey of 200 National Health Service nurses in the UK who administered vaccinations to children. The authors reported that administration of the fully liquid vaccine saved 4 minutes and 47 seconds across three doses when compared to a vaccine which required reconstitution (non-fully-liquid vaccine). Wiedenmayer et al[@b3-ppa-9-1517] observed 312 vaccinations in India and found that the fully liquid vaccine saved 46 seconds on average, when compared to the non-fully-liquid vaccine. Lafuma and Mara[@b4-ppa-9-1517] reported that injectable fully liquid products saved 52 seconds on average, decreasing the time spent on injection preparation by 35%. More recently, De Coster et al[@b5-ppa-9-1517] also reported in a population of 96 physicians and nurses that time needed to prepare a fully liquid hexavalent vaccine was about 50% lower than time needed to prepare a non-fully-liquid hexavalent vaccine. When considered in the context of mass immunization programs, these time savings can become quite significant. In the same study, these time savings were estimated to 664 days per year.[@b5-ppa-9-1517]

When we look at the data for HCPs overall, they indicate that they are almost twice as likely to choose a vaccine which has been used for over 3 years compared to one that has been in use for less than a year. However, this effect differed between the two groups. Physicians placed significantly more value on this attribute than nurses did and this aspect of preference has not been explored previously in research and may be an important consideration for decision making. Both groups significantly preferred being able to reduce preparation time to just 30 seconds from 2 minutes. The physicians placed more value on this than the nurses, which may reflect their workload or their perceived value of their time. In previous work, HCPs have highlighted the importance of time saving and how much it can affect resource management.[@b3-ppa-9-1517]

The avoidance of handling errors and dosing errors was important to participants. Overall, the HCPs were twice as likely to choose an option where the probability of handling errors slips to only 1:500 vaccinations compared to 1:100. Handling errors included needlesticks, contamination, and missing vials. Physicians placed significantly more value than nurses on reducing this risk to 1:500. Interestingly, both physicians and nurses placed more value on avoiding dosage errors than handling errors. HCPs were over three times as likely to prefer a vaccine with the lowest risk of dosage errors. The physicians placed more importance or value on reducing this risk (specifically at the 1:500 risk). Sharp and Whyte[@b10-ppa-9-1517] report that PFSs provided more accurate dosage than reconstitution devices, which may also explain the preference for PFS in the current study.

In addition to the primary analysis and the split by type of HCP, a series of additional analyses was also undertaken to determine the influence of other variables on participants' preferences by exploring interaction terms on the analysis. Interesting differences did emerge here. For example, those HCPs engaged in the preparation of vaccines had a stronger preference for the fully liquid vaccine compared with HCPs who only administered vaccines. And those people who administered vaccines placed more value on vaccines which had been in use for a number of years. HCPs who administer vaccines placed more value on avoiding dosing errors compared with those involved in any preparation.

Further analyses explored the influence of the type of vaccine that the HCP had most experience with -- either fully liquid or non-fully-liquid vaccine. Experience with a specific vaccine clearly had a large effect on participants' preferences. For example, fully liquid hexavalent vaccine users had a strong preference for fully liquid syringes, and were significantly less concerned about the amount of time that a vaccine had been available for use. Fully liquid hexavalent vaccine users valued rapid preparation time more and were significantly less concerned about dosage errors.

There are some limitations to this work which should be considered. The survey was restricted to recruiting HCPs in Germany only. We believe that the results are representative of practice in Germany, but they may not generalize well to other countries. There are some important differences regarding how vaccination programs are organized in different countries and this could have quite a large effect on the results. In the UK, for example, pediatric vaccination programs are undertaken by nurses alone. It would be interesting therefore to extend this work to other countries to see how these preference weights vary. The study was undertaken relatively soon after fully liquid hexavalent vaccine was introduced into the German market, and the distribution of fully liquid hexavalent vaccine and non-fully-liquid hexavalent vaccine users in the survey may not represent the current distribution. This is a source of potential bias. Over time as physicians gain greater experience of the use of the fully liquid hexavalent vaccines, we can speculate that they may value such features (convenience, speed etc) more highly.

This study has provided extensive detail regarding the views of different HCPs about hexavalent vaccinations for children. The survey focused on issues related more to the process of giving vaccinations, such as the use of fully liquid hexavalent vaccines, the importance of errors, reducing preparation time, and also the views of HCPs regarding the value that arises or accrues through the use of vaccines over several years. The findings indicated that, overall, all HCPs preferred fully liquid vaccines but there were some differences between nurses and physicians. This study identifies the aspects of hexavalent vaccination devices that HCPs in Germany consider important.
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###### 

Attribute list with associated descriptions and the levels that were used in the survey

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Attribute                                                                                                                              Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Level
  -------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------
  Type of device                                                                                                                         The hexavalent vaccine injection device can either be a PFS or an injection device which requires reconstitution. This feature will relate to whether you prefer one device or the other. The reconstitution injection device includes two consumables (syringe and vial), and the ready-to-use device includes one consumable, which is a PFS. Later in the survey, you will be presented with hypothetical devices which will either be a PFS or a reconstitution device.                                                                                                                                                                                                                • An injection device set that includes a ready-to-use PFS, with one consumable used\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • An injection device set that includes two consumables and requires reconstitution

  Experience of using this hexavalent vaccine device available on the German market                                                      This feature relates to the experience that HCPs would have with a hexavalent vaccine injection device that is available in the German market. For this feature, please imagine that there is a device which has been available on the German market for a number of years and you have experience of using this vaccine device. Later on in the survey, we will present you with hypothetical hexavalent injection devices and ask you to imagine the number of years you have had experience of using them.                                                                                                                                                                              • HCPs have had less than 1 year of experience\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • HCPs have had between 1 and 3 years of experience\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • HCPs have had more than 3 years of experience

  Preparation time                                                                                                                       Different hexavalent injection devices can vary in the number of steps and minutes it takes to prepare them before administering the vaccination with the device. For example, with a reconstitution device you will take the vial from the fridge, remove the cap from the vial, inject the contents of the vial into the syringe, mix and shake, aspire the content vial into the syringe, and discard the vial. With a PFS, once removed from the fridge, you shake the device well, remove the cap, and the device is ready to use. Later on in the survey, we will ask you to consider hypothetical hexavalent injection devices which will vary in the time taken to prepare them.   • 30 seconds\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • 1 minute\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • 2 minutes

  Probability of handling errors related to the number of preparation steps (eg, contamination, missing vials, and needlestick injury)   This feature relates to the number of steps involved in preparing different hexavalent vaccine injection devices for administration. Each additional step increases the probability of manipulation errors such as contamination or needlestick injuries to the HCP, which would mean that device and that vaccine, would have to be discarded. Later on in the survey, please imagine that you have been asked to use a hypothetical injection device, which may vary in the number of preparation steps and therefore the probability of handling errors.                                                                                                                                • An error will occur in 1 in 100 vaccinations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • An error will occur in 1 in 200 vaccinations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • An error will occur in 1 in 500 vaccinations

  Probability of dosage errors (eg, liquid left in a vial, wastage)                                                                      Sometimes, it is possible that when using the injection device to administer the hexavalent vaccine, the entire contents of the vaccine is not used/drawn or the lyophilized vaccine component may have been missed when preparing the injection device. If this occurs, this could lead to the infant not receiving the full hexavalent vaccine dosage. Later on in the survey, the hypothetical injection devices that you are presented with may vary in terms of the probability of such errors of dosage occurring.                                                                                                                                                                   • An error will occur in 1 in 100 vaccinations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • An error will occur in 1 in 500 vaccinations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • An error will occur in 1 in 1,000 vaccinations
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** HCP, health care professionals; PFS, prefilled syringe.

###### 

Sociodemographic and current clinical practice profile of the sample by profession

                                                                                                      Total (n=300)             Physician (n=150)          Nurse (n=150)
  --------------------------------------------------------------------------------------------------- ------------------------- -------------------------- -------------------------
  Male, n (%)                                                                                         143 (47.7)                103 (68.7)                 40 (26.7)
  Median age range                                                                                    45--50 years old          51--54 years old           35--40 years old
  Number of hexavalent vaccines prepared/administered per month                                                                                            
                                                                                                      Between 1 and 250 doses   Between 10 and 250 doses   Between 1 and 160 doses
  Current role, n (%)                                                                                                                                      
   Only prepare                                                                                       81 (27.0)                 2 (1.3)                    79 (52.7)
   Only administer                                                                                    117 (39.0)                103 (68.7)                 14 (9.3)
   Prepare and administer                                                                             102 (34.0)                45 (30.0)                  57 (38.0)
  Vaccine used most frequently, n (%)                                                                                                                      
   Hexyon                                                                                             98 (32.7)                 40 (26.7)                  58 (38.7)
   Infanrix-hexa                                                                                      202 (67.3)                110 (73.3)                 92 (61.3)
  Vaccine device used most often, n (%)                                                                                                                    
   Non-fully-liquid (requires reconstitution)                                                         135 (45.0)                100 (66.7)                 35 (23.3)
   Fully liquid (ready-to-use)                                                                        165 (55.0)                50 (33.3)                  115 (76.7)
  Number of years a hexavalent vaccine has been available is important to HCP, n (%)                                                                       
   Yes                                                                                                124 (41.3)                72 (48.0)                  52 (34.7)
   No                                                                                                 176 (58.7)                78 (52.0)                  98 (65.3)
  Number of years a vaccine has been available influences HCP's choice of hexavalent vaccine, n (%)                                                        
   Yes                                                                                                123 (41.0)                71 (47.3)                  52 (34.7)
   No                                                                                                 177 (59.0)                79 (52.7)                  98 (65.3)
  Number of years HCP has with using their current hexavalent vaccine, n (%)                                                                               
   \<1 years                                                                                          38 (12.7)                 22 (14.7)                  16 (10.7)
   1--3 years                                                                                         86 (28.7)                 22 (14.7)                  64 (42.7)
   \>3 years                                                                                          176 (58.7)                106 (70.7)                 70 (46.7)
  Estimate number of seconds/minutes to prepare vaccine (currently), n (%)                                                                                 
   30 seconds                                                                                         96 (32.0)                 48 (32.0)                  48 (32.0)
   1 minute                                                                                           161 (53.7)                76 (50.7)                  85 (56.7)
   2 minutes                                                                                          43 (14.3)                 26 (17.3)                  17 (11.3)
  How often a handling error with a hexavalent vaccination has occurred, n (%)                                                                             
   Never                                                                                              116 (38.7)                60 (40.0)                  56 (37.3)
   One in 1,000 vaccinations                                                                          95 (31.7)                 54 (36.0)                  41 (27.3)
   One in 500 vaccinations                                                                            39 (13.0)                 21 (14.0)                  18 (12.0)
   One in 200 vaccinations                                                                            36 (12.0)                 13 (8.7)                   23 (15.3)
   One in 100 vaccinations                                                                            14 (4.7)                  2 (1.3)                    12 (8.0)
  How often a dosage error with a hexavalent vaccination has occurred, n (%)                                                                               
   Never                                                                                              168 (56.0)                94 (62.7)                  74 (49.3)
   One in 1,000 vaccinations                                                                          56 (18.7)                 26 (17.3)                  30 (20.0)
   One in 500 vaccinations                                                                            31 (10.3)                 17 (11.3)                  14 (9.3)
   One in 200 vaccinations                                                                            29 (9.7)                  11 (7.3)                   18 (12.0)
   One in 100 vaccinations                                                                            16 (5.3)                  2 (1.3)                    14 (9.3)

**Abbreviation:** HCP, health care professional.

###### 

Results of the conditional logit model, for preferences of attributes

  Attribute                                                           Level[a](#tfn3-ppa-9-1517){ref-type="table-fn"}            Total (n=300)                                              Physician (n=150)                                          Nurse/Clinical assistant (n=150)                                                                                                                                                 
  ------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------
  Type of device                                                      Fully liquid                                               1.591^002A^ (0.036)                                        1.483, 1.707                                               1.450[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.051)   1.312, 1.602                                               1.755[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.051)   1.588, 1.939
  Requires reconstitution[b](#tfn4-ppa-9-1517){ref-type="table-fn"}   --                                                         --                                                         --                                                         --                                                         --                                                         --                                                         
  Years of experience using hexavalent vaccine                        \>3 years                                                  1.845[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.048)   1.662, 2.048                                               2.257[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.077)   1.940, 2.626                                               1.513[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.075)   1.307, 1.751
  1--3 years[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}               1.675[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.053)   1.525, 1.840                                               1.848[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.070)   1.612, 2.119                                               1.538[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.067)   1.350, 1.753                                               
  \<1 year[b](#tfn4-ppa-9-1517){ref-type="table-fn"}                  --                                                         --                                                         --                                                         --                                                         --                                                         --                                                         
  Preparation time                                                    30 seconds[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}      2.331[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.056)   2.090, 2.599                                               2.449[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.081)   2.089, 2.870                                               2.241[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.077)   1.928, 2.606
  1 minute[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}                 1.698[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.046)   1.552, 1.857                                               1.832[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.065)   1.612, 2.082                                               1.581[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.065)   1.392, 1.795                                               
  2 minutes[b](#tfn4-ppa-9-1517){ref-type="table-fn"}                 --                                                         --                                                         --                                                         --                                                         --                                                         --                                                         
  Probability of handling errors                                      One in 500[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}      2.100[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.052)   1.895, 2.327                                               2.268[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.074)   1.960, 2.624                                               1.951[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.074)   1.687, 2.256
  One in 200[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}               1.482[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.046)   1.353, 1.623                                               1.541[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.067)   1.351, 1.759                                               1.427[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.065)   1.257, 1.621                                               
  One in 100[b](#tfn4-ppa-9-1517){ref-type="table-fn"}                --                                                         --                                                         --                                                         --                                                         --                                                         --                                                         
  Probability of dosage error                                         One in 1,000[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}    3.727[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.054)   3.350, 4.145                                               3.615[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.078)   3.101, 4.215                                               3.954[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.077)   3.400, 4.598
  One in 500[\*](#tfn5-ppa-9-1517){ref-type="table-fn"}               2.489[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.046)   2.273, 2.725                                               2.572[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.067)   2.256, 2.933                                               2.439[\*](#tfn5-ppa-9-1517){ref-type="table-fn"} (0.065)   2.149, 2.768                                               
  One in 100[b](#tfn4-ppa-9-1517){ref-type="table-fn"}                --                                                         --                                                         --                                                         --                                                         --                                                         --                                                         

**Notes:**

The reconstitution level or the worse level of each attribute is used as the reference case;

reference cases;

significant at *P*\<0.001.

**Abbreviations:** OR, odds ratio; SE, standard error; CI, confidence interval.
